Author: Umoja Biopharma, Inc.

Umoja Biopharma Announces Oral Presentation of First UB-VV400 In Vivo CAR T Cell Therapy Clinical Data and Four Total Presentations at the 68th ASH Annual Meeting

November 4, 2026
Umoja Biopharma Announces FDA Clearance of IND Application for UB-VV400, the Industry’s First Known CD22-Directed In Vivo CAR T Cell Therapy for Relapsed/Refractory B Cell Malignancies

July 16, 2026

Umoja Biopharma Announces Oral Presentation of First UB-VV400 In Vivo CAR T Cell Therapy Clinical Data and Four Total Presentations at the 68th ASH Annual Meeting